INAMED Files Amendment with FDA for BioDimensional(TM) Style 410 Matrix Cohesive

[Guest guest]

Press Release Source: INAMED Corporation

INAMED Files Amendment with FDA for BioDimensional Style 410 Matrix Cohesive

Gel

Implant PMA

Thursday November 17, 8:00 pm ET

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Nov. 17, 2005--INAMED Corporation

(NASDAQ:IMDC - News), a global healthcare company, today announced that it has

submitted an amendment to its cohesive gel breast implant (BioDimensional

Style 410

Matrix) premarket approval application (PMA) currently under review by the Food

and Drug

Administration (FDA). The Style 410 PMA was submitted to the FDA in December

2004.

ADVERTISEMENT

Among other information submitted to the FDA, the Company provided 3-year

follow-up

data from the Style 410 Core Study cohort and new 5-9-year rupture prevalence

data from

a European study.

" We are pleased to have submitted this amendment to our Style 410 PMA, " said

Nick Teti,

Chairman, President and Chief Executive Officer. " We look forward to continuing

our

discussions with the FDA regarding this important product. "

The innovative BioDimensional Style 410 is the next generation of cohesive gel

implant in

INAMED's pipeline undergoing U.S. clinical studies. The product is designed for

memory

and shape retention and has been available internationally for almost 10 years.

About INAMED Corporation

INAMED is a global healthcare company with over 25 years of experience

developing,

manufacturing and marketing innovative, high-quality, science-based products.

Current

products include breast implants for aesthetic augmentation and for

reconstructive

surgery; a range of dermal products to treat facial wrinkles; and minimally

invasive devices

for obesity intervention, including the LAP-BAND® System for morbid obesity. The

Company's website is www.Inamed.com.

Forward-Looking Statements

This press release contains, in addition to historical information,

forward-looking

statements. Such statements are based on management's current estimates and

expectations and are subject to a number of uncertainties and risks that could

cause

actual results to differ or differ materially from those described in the

forward-looking

statements. INAMED is providing this information as of November 17, 2005, and

expressly

disclaims any duty to update information contained in this press release.

This press release contains additional forward-looking statements about INAMED's

U.S.

silicone breast implant clinical studies and certain investigational devices,

including

without limitation, clinical data obtained from the studies and clinical data

submitted to

the FDA. These forward-looking statements involve risks and uncertainties,

including

unknown risks associated with the investigational devices that are the subject

of INAMED's

clinical studies, including the Style 410 implant, which could cause actual

results to differ

materially from those expressed or implied here. Readers are referred to the

documents

filed by INAMED with the Securities and Exchange Commission, specifically the

most

recent reports which identify important risk factors that could cause actual

results to differ

from those contained in the forward-looking statements.

The information contained in this press release is a statement of INAMED's

present

intention, belief or expectation and is based upon, among other things, the

existing

regulatory environment, industry conditions, market conditions and prices, the

economy

in general, and INAMED's assumptions. INAMED may change its intention, belief or

expectation, at any time and without notice, based upon any changes in such

factors,

assumptions or otherwise. INAMED undertakes no obligation to review or confirm

analysts'

expectations or estimates or to state publicly any revisions to any

forward-looking

statements to reflect events or circumstances after the date hereof or to

reflect the

occurrence of unanticipated events.

By including any information in this press release, INAMED does not necessarily

acknowledge that disclosure of such information is required by applicable law or

that the

information is material.